Clinical Trials Insight: 700030270
Phase of Trial: Phase II
Latest Information Update: 30 May 2009
At a glance
- Drugs PX 12 (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Sponsors Cascadian Therapeutics
- 30 May 2009 Status changed from not yet recruiting to suspended. Enrolled has been suspended in all PX 12 trials. Oncothyreon is looking for a partner to continue development with this drug.
- 01 Feb 2008 New trial record.